TremRx

Blood & Organ Banks · Massachusetts, United States · 11-50 Employees

View Company Info for Free

Overview

Headquarters

67 Broad St, Boston, Massachusetts, 0210...

Phone Number

(781) 863-0933

Revenue

$5.1 Million

Industry

Blood & Organ Banks Business Services Healthcare Services Research & Development
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1

About TremRx

TremRx is a biotechnology company that is developing novel prophylactic and therapeutic vaccines that can achieve higher levels of efficacy and safety by employing dramatically new ways to create and administer vaccines. The company's approach is based on scientific discoveries that open a new path for vaccines that create a more effective immune response than today's conventional vaccines. TremRx's novel vaccines are different in two ways: TremRx vaccines are created using engineered replication-deficient viruses that have safety advantages over vaccines that employ replicating viruses; TremRx vaccines are applied to an abraded upper layer of the skin rather than by injection into the muscles or bloodstream. TremRx's novel approach to vaccines is based on a groundbreaking discovery that shows that vaccines that are delivered to the upper skin tissues are able to induce the production of powerful cells of the immune system, called TREMs (T Resident Effector Memory cells). The inductionRead more
Popular SearchesTremRx IncTREM Rx IncTremRxSIC Code 28,283NAICS Code 32,325Show more

Is TremRx your ideal customer?

Let us give you the heads up on whether it's a good time to reach out

Recommended Actions

Compare Similar Companies to TremRx

Compare insights from companies similar to TremRx, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.

Company Name

Revenue

Number of Employees

Type

Funding

Founded In

Top Executive

TremRx

$5.1M
11-50
Private
-
-
N/A
$24.3M
11-50
Private
$29.7M
2003
SO
Shawn O'BrienPresident & CEO
$14M
51-200
Private
$31.9M
1997
AG
Andrew GrahamTechnical Operations Vice President, Development
<$5M
11-50
Private
-
2018
MC
Mark ChenVice President, Business Development
<$5M
11-50
Public
$547.7M
2007
JS
Jay ShortChairman, CEO & Co-Founder
<$5M
1-10
Private
-
2012
N/A
<$5M
1-10
Private
-
1998
Illustration of an envelope

TremRx Tech Stack

A closer look at the technologies used by TremRx

Top Blood & Organ Banks Companies

Frequently Asked Questions Regarding TremRx

What is TremRx's official website?
TremRx's official website is www.tremrx.com
What is TremRx's Revenue?
TremRx's revenue is $5.1 Million
What is TremRx's SIC code?
TremRx's SIC: 28,283
What is TremRx's NAICS code?
TremRx's NAICS: 32,325
How many employees does TremRx have?
TremRx has 11-50 employees
What industry does TremRx belong to?
TremRx is in the industry of: Blood & Organ Banks, Business Services, Healthcare Services
What is TremRx competition?
TremRx top competitors include: AlphaVax, AbVision, GeneCure, BioAtla
What technology does TremRx use?
Some of the popular technologies that TremRx uses are: PHP, Cloudflare Website Optimization, Cloudflare CDN, jQuery
How do I contact TremRx?
TremRx contact info: Phone number: (781) 863-0933 Website: www.tremrx.com
What does TremRx do?

TremRx is a biotechnology company that is developing novel prophylactic and therapeutic vaccines that can achieve higher levels of efficacy and safety by employing dramatically new ways to create and administer vaccines. The company's approach is based on scientific discoveries that open a new path for vaccines that create a more effective immune r... esponse than today's conventional vaccines. TremRx's novel vaccines are different in two ways: TremRx vaccines are created using engineered replication-deficient viruses that have safety advantages over vaccines that employ replicating viruses; TremRx vaccines are applied to an abraded upper layer of the skin rather than by injection into the muscles or bloodstream. TremRx's novel approach to vaccines is based on a groundbreaking discovery that shows that vaccines that are delivered to the upper skin tissues are able to induce the production of powerful cells of the immune system, called TREMs (T Resident Effector Memory cells). The induction of TREMs enables vaccines to produce a stronger and more effective protective or therapeutic immune response. Although it is well established that T-cells can deliver a strong immune response, it was previously thought that memory T cells circulating in blood provided this protection. Until very recently, it was unknown that a large and active population of TREMs existed in skin and other epithelial tissues. Because of the strong immune response produced by TREMs in epithelial tissues, TremRx has developed a proprietary technology platform that creates a novel class of vaccines incorporating replication-deficient engineered viruses delivered to skin cells. TremRx's replication-deficient vaccines may also have significant safety advantages, particularly since such vaccines may be administered to individuals with compromised immune systems. TremRx has a robust intellectual property estate based on new patent filings as well as the vaccine-relevant intellectual property from the discoveries of Dr. Thomas S. Kupper, Chief of ...Read More

Is TremRx a public company?
TremRx is private company therefore does not currently have an official ticker symbol
See more information about TremRx

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.